Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.

Dajani A, AbuHammour A.

Saudi J Gastroenterol. 2016 Mar-Apr;22(2):91-105. doi: 10.4103/1319-3767.178527. Review.

2.

Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Takahashi Y, Sugimoto K, Inui H, Fukusato T.

World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777. Review.

3.

[Treatment Options in Non-alcoholic Fatty Liver Disease].

Kim W.

Korean J Gastroenterol. 2017 Jun 25;69(6):353-358. doi: 10.4166/kjg.2017.69.6.353. Review. Korean.

4.

Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Gawrieh S, Chalasani N.

Clin Liver Dis. 2018 Feb;22(1):189-199. doi: 10.1016/j.cld.2017.08.013. Epub 2017 Oct 10. Review.

PMID:
29128056
5.

The therapeutic landscape of non-alcoholic steatohepatitis.

Perazzo H, Dufour JF.

Liver Int. 2017 May;37(5):634-647. doi: 10.1111/liv.13270. Epub 2016 Nov 7. Review.

PMID:
27727520
6.

Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.

Ganesh S, Rustgi VK.

Clin Liver Dis. 2016 May;20(2):351-64. doi: 10.1016/j.cld.2015.10.009. Epub 2016 Feb 19. Review.

PMID:
27063274
7.

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.

Makri E, Cholongitas E, Tziomalos K.

World J Gastroenterol. 2016 Nov 7;22(41):9039-9043.

8.

Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Golabi P, Bush H, Younossi ZM.

Clin Liver Dis. 2017 Nov;21(4):739-753. doi: 10.1016/j.cld.2017.06.010. Epub 2017 Jul 29. Review.

PMID:
28987260
9.

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.

Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.

PMID:
23727264
10.

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.

Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L.

Drug Des Devel Ther. 2015 Aug 20;9:4835-45. doi: 10.2147/DDDT.S64877. eCollection 2015. Review.

11.

Modern approach to the clinical management of non-alcoholic fatty liver disease.

Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F.

World J Gastroenterol. 2014 Jul 14;20(26):8341-50. doi: 10.3748/wjg.v20.i26.8341. Review.

12.

Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C.

World J Gastroenterol. 2014 Dec 7;20(45):16841-57. doi: 10.3748/wjg.v20.i45.16841. Review.

13.

Nonalcoholic fatty liver disease: new treatments.

Hardy T, Anstee QM, Day CP.

Curr Opin Gastroenterol. 2015 May;31(3):175-83. doi: 10.1097/MOG.0000000000000175. Review.

14.

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.

Rotman Y, Sanyal AJ.

Gut. 2017 Jan;66(1):180-190. doi: 10.1136/gutjnl-2016-312431. Epub 2016 Sep 19. Review.

PMID:
27646933
15.

Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Vassilatou E.

World J Gastroenterol. 2014 Jul 14;20(26):8351-63. doi: 10.3748/wjg.v20.i26.8351. Review.

16.

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R.

Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29.

PMID:
23703580
17.

Emerging Therapies for Nonalcoholic Fatty Liver Disease.

Hameed B, Terrault N.

Clin Liver Dis. 2016 May;20(2):365-85. doi: 10.1016/j.cld.2015.10.015. Epub 2016 Feb 26. Review.

PMID:
27063275
18.

Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.

Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, Chaiyakunapruk N.

Medicine (Baltimore). 2016 Aug;95(32):e4529. doi: 10.1097/MD.0000000000004529. Review.

19.

Current management of non-alcoholic fatty liver disease.

Lisboa QC, Costa SM, Couto CA.

Rev Assoc Med Bras (1992). 2016 Dec;62(9):872-878. doi: 10.1590/1806-9282.62.09.872.

20.

Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.

Oh H, Jun DW, Saeed WK, Nguyen MH.

Clin Mol Hepatol. 2016 Sep;22(3):327-335. Epub 2016 Sep 25. Review.

Supplemental Content

Support Center